skip to main content

Cervical CRT Evidence — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

EasyGynaecological CancersCervical CRT EvidenceSCE Medical Oncology

A 55-year-old woman with cervical cancer is offered concurrent chemoradiotherapy. She asks about the evidence base. What landmark trial established concurrent cisplatin with radiotherapy for cervical cancer?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: D — Multiple trials including GOG 120

In 1999, the US NCI issued a rare clinical alert based on five randomised trials (GOG 120, GOG 123, RTOG 90-01, Keys et al, Peters et al) all showing OS benefit for concurrent cisplatin-based CRT over RT alone for cervical cancer. This was one of the most practice-changing moments in gynaecological oncology. Weekly cisplatin 40 mg/m² during RT became the global standard. The absolute OS benefit was approximately 10-15% at 5 years.

Reference: https://www.nice.org.uk/guidance/conditions-and-diseases/cancer